Percheron Therapeutics Ltd
ASX:PER

Watchlist Manager
Percheron Therapeutics Ltd Logo
Percheron Therapeutics Ltd
ASX:PER
Watchlist
Price: 0.074 AUD Market Closed
Market Cap: 76.7m AUD
Have any thoughts about
Percheron Therapeutics Ltd?
Write Note

Intrinsic Value

PER's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PER stock under the Base Case scenario is 0.067 AUD. Compared to the current market price of 0.074 AUD, Percheron Therapeutics Ltd is Overvalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PER Intrinsic Value
0.067 AUD
Overvaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Percheron Therapeutics Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PER cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PER?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Percheron Therapeutics Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Percheron Therapeutics Ltd

Provide an overview of the primary business activities
of Percheron Therapeutics Ltd.

What unique competitive advantages
does Percheron Therapeutics Ltd hold over its rivals?

What risks and challenges
does Percheron Therapeutics Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Percheron Therapeutics Ltd.

Provide P/S
for Percheron Therapeutics Ltd.

Provide P/E
for Percheron Therapeutics Ltd.

Provide P/OCF
for Percheron Therapeutics Ltd.

Provide P/FCFE
for Percheron Therapeutics Ltd.

Provide P/B
for Percheron Therapeutics Ltd.

Provide EV/S
for Percheron Therapeutics Ltd.

Provide EV/GP
for Percheron Therapeutics Ltd.

Provide EV/EBITDA
for Percheron Therapeutics Ltd.

Provide EV/EBIT
for Percheron Therapeutics Ltd.

Provide EV/OCF
for Percheron Therapeutics Ltd.

Provide EV/FCFF
for Percheron Therapeutics Ltd.

Provide EV/IC
for Percheron Therapeutics Ltd.

Show me price targets
for Percheron Therapeutics Ltd made by professional analysts.

What are the Revenue projections
for Percheron Therapeutics Ltd?

How accurate were the past Revenue estimates
for Percheron Therapeutics Ltd?

What are the Net Income projections
for Percheron Therapeutics Ltd?

How accurate were the past Net Income estimates
for Percheron Therapeutics Ltd?

What are the EPS projections
for Percheron Therapeutics Ltd?

How accurate were the past EPS estimates
for Percheron Therapeutics Ltd?

What are the EBIT projections
for Percheron Therapeutics Ltd?

How accurate were the past EBIT estimates
for Percheron Therapeutics Ltd?

Compare the revenue forecasts
for Percheron Therapeutics Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Percheron Therapeutics Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Percheron Therapeutics Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Percheron Therapeutics Ltd compared to its peers.

Compare the P/E ratios
of Percheron Therapeutics Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Percheron Therapeutics Ltd with its peers.

Analyze the financial leverage
of Percheron Therapeutics Ltd compared to its main competitors.

Show all profitability ratios
for Percheron Therapeutics Ltd.

Provide ROE
for Percheron Therapeutics Ltd.

Provide ROA
for Percheron Therapeutics Ltd.

Provide ROIC
for Percheron Therapeutics Ltd.

Provide ROCE
for Percheron Therapeutics Ltd.

Provide Gross Margin
for Percheron Therapeutics Ltd.

Provide Operating Margin
for Percheron Therapeutics Ltd.

Provide Net Margin
for Percheron Therapeutics Ltd.

Provide FCF Margin
for Percheron Therapeutics Ltd.

Show all solvency ratios
for Percheron Therapeutics Ltd.

Provide D/E Ratio
for Percheron Therapeutics Ltd.

Provide D/A Ratio
for Percheron Therapeutics Ltd.

Provide Interest Coverage Ratio
for Percheron Therapeutics Ltd.

Provide Altman Z-Score Ratio
for Percheron Therapeutics Ltd.

Provide Quick Ratio
for Percheron Therapeutics Ltd.

Provide Current Ratio
for Percheron Therapeutics Ltd.

Provide Cash Ratio
for Percheron Therapeutics Ltd.

What is the historical Revenue growth
over the last 5 years for Percheron Therapeutics Ltd?

What is the historical Net Income growth
over the last 5 years for Percheron Therapeutics Ltd?

What is the current Free Cash Flow
of Percheron Therapeutics Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Percheron Therapeutics Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Percheron Therapeutics Ltd

Current Assets 14.5m
Cash & Short-Term Investments 11.9m
Receivables 2.6m
Other Current Assets 38.3k
Non-Current Assets 56.9k
PP&E 56.9k
Current Liabilities 5.2m
Accounts Payable 3.7m
Accrued Liabilities 1.1m
Other Current Liabilities 286.2k
Non-Current Liabilities 15.2k
Other Non-Current Liabilities 15.2k
Efficiency

Earnings Waterfall
Percheron Therapeutics Ltd

Revenue
615.5k AUD
Operating Expenses
-14.9m AUD
Operating Income
-14.3m AUD
Other Expenses
2.3m AUD
Net Income
-11.9m AUD

Free Cash Flow Analysis
Percheron Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PER Profitability Score
Profitability Due Diligence

Percheron Therapeutics Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional ROIC
ROE is Increasing
40/100
Profitability
Score

Percheron Therapeutics Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

PER Solvency Score
Solvency Due Diligence

Percheron Therapeutics Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
Long-Term Solvency
Short-Term Solvency
67/100
Solvency
Score

Percheron Therapeutics Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PER Price Targets Summary
Percheron Therapeutics Ltd

Wall Street analysts forecast PER stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PER is 0.218 AUD with a low forecast of 0.152 AUD and a high forecast of 0.263 AUD.

Lowest
Price Target
0.152 AUD
105% Upside
Average
Price Target
0.218 AUD
194% Upside
Highest
Price Target
0.263 AUD
255% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PER?

Click here to dive deeper.

Dividends

Percheron Therapeutics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for PER is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Percheron Therapeutics Ltd Logo
Percheron Therapeutics Ltd

Country

Australia

Industry

Pharmaceuticals

Market Cap

76.7m AUD

Dividend Yield

0%

Description

Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.

Contact

VICTORIA
Melbourne
14 Wallace Avenue,, Toorak
+61398278999
www.antisense.com.au

IPO

2001-12-20

Employees

-

Officers

CEO, MD & Director
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Company Secretary & CFO
Ms. Deborah Ambrosini B.Com., F.C.A.
Chief Operating Officer
Dr. Anthony Filippis
Chief Medical Advisor
Dr. Cathryn M. Clary M.B.A., M.D.

See Also

Discover More
What is the Intrinsic Value of one PER stock?

The intrinsic value of one PER stock under the Base Case scenario is 0.067 AUD.

Is PER stock undervalued or overvalued?

Compared to the current market price of 0.074 AUD, Percheron Therapeutics Ltd is Overvalued by 9%.

Back to Top